Suloctidil was a sulfur-containing aminoalcohol that was brought to market in the early 1970s as a vasodilator by Continental Pharma, a Belgian company.

[1]: 118–121 [2][3] Continental was bought by Monsanto in 1984, primarily on the promise of sales of suloctidil, which was approved in Europe at the time, but not in the US.

[4] However, in 1985 Monsanto halted development and withdrew the drug worldwide following reports of liver toxicity.

This drug article relating to the cardiovascular system is a stub.

You can help Wikipedia by expanding it.